Faster global financial news!
Wegovy
-
Novo Nordisk's next-generation obesity drug CagriSema showed an average weight reduction of 25% in women in a late-stage analysis.
Danish pharmaceutical giant Novo Nordisk on Tuesday released updated late-stage analysis data for its next-generation experimental obesity drug, CagriSema. The results showed that among approximately
-
Novo Nordisk seeks national health insurance coverage for Wegovy in Korea
Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for reimbursement of its obesity drug Wegovy, pharmaceutical industry sources said Tuesday. This move aims to signi
-
Novo Nordisk's Wegovy shows positive results in child obesity trial, but market adoption faces hurdles; shares down 17% over past year
Novo Nordisk's (NYSE:NVO) Phase 3 STEP Young trial for its obesity drug semaglutide (Wegovy) showed positive results in children aged six to under twelve, with a meaningful share moving below the clin
-
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
-
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
-
Novo Nordisk's next-generation obesity drug CagriSema showed an average weight reduction of 25% in women in a late-stage analysis.
Danish pharmaceutical giant Novo Nordisk on Tuesday released updated late-stage analysis data for its next-generation experimental obesity drug, CagriSema. The results showed that among approximately
-
Novo Nordisk seeks national health insurance coverage for Wegovy in Korea
Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for reimbursement of its obesity drug Wegovy, pharmaceutical industry sources said Tuesday. This move aims to signi
-
Novo Nordisk's Wegovy shows positive results in child obesity trial, but market adoption faces hurdles; shares down 17% over past year
Novo Nordisk's (NYSE:NVO) Phase 3 STEP Young trial for its obesity drug semaglutide (Wegovy) showed positive results in children aged six to under twelve, with a meaningful share moving below the clin
-
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
-
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
- No data
Wegovy
24H Trending
-
1
Top 10 Cryptocurrency Exchanges Ranking: Public Data Review for 2024–2026
-
2
Hebron Governor stated that Israeli forces have withdrawn from the city, with Palestinian security forces now in full control.
-
3
Current Status of Bitcoin Trading Platforms in Mainland China: Policy Interpretation and Risk Warning
-
4
Cardano (ADA) Investment Analysis: In-depth Look at Risks and Rewards
-
5
Euronext Joins Nordic Compass Alliance to Integrate Regional Capital Markets
-
6
Swire Properties CEO says company is exploring C-Reits for its mainland Chinese commercial assets to unlock capital
-
7
ELAMA Coin Status Analysis: The Silence and Challenges of an Enterprise Blockchain Project
-
8
SHIB Price Trends and Latest Developments Analysis
-
9
Tether's Global Expansion Strategy: A Vision for a Global Currency
-
10
South Korean financial firms, including Mirae Asset, Hanwha, and Toss, are accelerating their expansion into the Japanese market, planning to acquire local brokerages to capitalize on a surge in retail investment and capital market reforms.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
